Growth hormone deficiency market to expand at a steady CAGR of 3.9%

24 May 2017

The global growth hormone deficiency (GHD) space, which covers the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from around $1.42 billion in 2016 to $2.08 billion by 2026, representing a steady compound annual growth rate (CAGR) of 3.9%.

According to research and consulting firm GlobalData’s latest report, the major drivers of this growth include the launch of long-acting growth hormones, improved adherence to and compliance with the use of these growth hormones, and increased awareness of the disease within the medical profession.

Edit Kovalcsik, healthcare analyst for GlobalData, explains: “Patient compliance with daily growth hormone drugs has been a long-standing issue in the GHD treatment landscape, and remains the greatest unmet need in the market. This unmet need has given a major thrust to innovation in the treatment space, with pharmaceutical companies focusing heavily on developing easier delivery options for patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK